Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 995,395 shares, a drop of 23.9% from the February 26th total of 1,307,493 shares. Based on an average daily volume of 1,654,814 shares, the short-interest ratio is presently 0.6 days. Approximately 3.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Liminatus Pharma Stock Down 2.9%

LIMN stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.17. 1,711,803 shares of the stock traded hands, compared to its average volume of 8,892,019. The firm has a market capitalization of $5.34 million and a PE ratio of -1.43. The business has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.90. Liminatus Pharma has a 52 week low of $0.17 and a 52 week high of $33.66.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.